Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Hinge Health, Inc. reported an insider-related share sale involving a major shareholder. A director and 10% owner filed to report sales made by affiliated Bessemer venture funds on December 5, 2025. Bessemer Venture Partners X L.P. sold 2,614 shares of Class A common stock and Bessemer Venture Partners X Institutional L.P. sold 2,453 shares at a weighted average price of $50.0166, in multiple trades between $50.00 and $50.12. The reporting person is a partner at Bessemer Venture Partners and describes only an indirect, passive economic interest in these fund-held shares, formally disclaiming beneficial ownership beyond any pecuniary interest.
Bessemer Venture Partners affiliates filed a Form 144 indicating planned sales of HNGE Class A shares. The notice covers 2,453 Class A shares to be sold through Merrill Lynch, with an aggregate market value of $122,453.76 and 37,919,155 Class A shares outstanding as context. The approximate sale date is listed as December 5, 2025 on the NYSE.
The securities to be sold were acquired in a private placement from the issuer on February 4, 2020 and paid for in cash. The filing also reports multiple prior Class A sales during November 2025 by Bessemer Venture Partners X LP and Bessemer Venture Partners X Institutional LP, including blocks of 373,955 and 351,045 shares, each generating multi‑million dollar gross proceeds.
HNGE shareholders filed a Form 144 indicating an intent to sell 2,614 Class A shares through Merrill Lynch on the NYSE. The planned sale has an aggregate market value of 130,490.88, with Class A shares outstanding reported at 37,919,155. These shares were originally acquired from the issuer in a private placement on 02/04/2020 and paid for in cash on the same date.
Over the past three months, affiliated holders have already sold several large Class A blocks. Bessemer Venture Partners X LP reported sales including 373,955 shares on 11/18/2025 for gross proceeds of 14,976,898, 103,160 shares on 11/26/2025 for 4,979,533.2, and 23,176 shares on 11/28/2025 for 1,162,403.87. Bessemer Venture Partners X Institutional LP reported sales including 351,045 shares on 11/18/2025 for 14,059,352, 96,840 shares on 11/26/2025 for 4,674,466.8, and 21,757 shares on 11/28/2025 for 1,091,233.21.
Insight Venture Partners affiliates, identified as a director and 10% owner of Hinge Health, Inc. (HNGE), reported on Form 4 that on December 1, 2025 they converted multiple blocks of Class B Common Stock into Class A Common Stock and then sold those Class A shares.
The reporting persons converted and sold 826,216, 19,659, 677,508 and 131,057 shares of Class B/Class A stock, respectively, through affiliated Insight investment funds, with each corresponding Class A position shown as reduced to zero following the sales at a reported price of $47.76 per share.
Footnotes describe that each share of Class B Common Stock was convertible into one share of Class A Common Stock and outline Insight’s fund and holding-company structure, noting that various Insight entities and managers may be deemed to share voting and dispositive power over these Hinge Health shares while generally disclaiming beneficial ownership beyond their pecuniary interests.
HNGE filed a notice under Rule 144 for a proposed sale of restricted or control securities. The filing covers the planned sale of 19,659 shares of Class A stock through broker Merrill Lynch, with an aggregate market value of 961,521.69. These shares are part of a larger base of 37,919,155 shares outstanding and are expected to be sold on the NYSE on or about 12/01/2025. The seller originally acquired the 19,659 Class A shares from the issuer in a private placement on 07/03/2018, paying cash at that time.
HNGE has a shareholder planning to sell 131,057 Class A shares through Merrill Lynch on the NYSE, with an aggregate market value of $6,409,997.87. The filing notes that 37,919,155 shares of this class are outstanding. The shares to be sold were originally acquired from the issuer in a private placement on 07/03/2018 for cash.
HNGE has a shareholder filing a Form 144 notice to sell up to 677,508 Class A shares through Merrill Lynch on the NYSE, with an approximate aggregate market value of
HNGE reported that a holder of its Class A stock has filed a notice of proposed sale under Rule 144. The holder plans to sell 826,216 Class A shares through Merrill Lynch on the NYSE, with an approximate sale date of 12/01/2025. The filing lists an aggregate market value for these shares of $40,410,224.56. These Class A shares were originally acquired from the issuer in a private placement on 07/03/2018 and paid for in cash. The notice also states that 37,919,155 shares of this class were outstanding, providing a baseline for the size of the proposed sale.
Hinge Health, Inc. reported an insider equity transaction by its President on 12/01/2025. The filing shows that 5,126 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $48.91 per share. This type of code indicates shares were withheld or surrendered to cover taxes associated with the vesting of restricted stock units, rather than being sold on the open market.
After this tax-related share cancellation, the reporting officer beneficially owns 784,776 shares of Class A common stock directly. The issuer satisfied the related federal and state tax withholding obligations in exchange for the relinquished shares, leaving the executive with a substantial continuing equity stake in the company.
Hinge Health, Inc.'s Chief Financial Officer reported a routine share disposition related to tax withholding on equity compensation. On 12/01/2025, the reporting person disposed of 8,213 shares of Class A common stock at $48.91 per share in an exempt transaction. After this transaction, the officer beneficially owned 471,665 shares directly.
The company explains that the shares were withheld and cancelled by the issuer to cover federal and state tax obligations arising from the vesting of restricted stock units, as permitted under Section 16b-3(e). This reflects standard administrative handling of equity awards rather than an open-market sale.